Pharmacogenetic approaches to cognitive enhancement in schizophrenia

Harvard Review of Psychiatry

Volumn 19, Issue 3, 2011, Pages 102-108

  Burdick, Katherine E ^a,b,c   Gopin, Chaya B ^b   Malhotra, Anil K ^a,b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

cognition; pharmacogenetics; schizophrenia

Indexed keywords

AMPHETAMINE; CATECHOL METHYLTRANSFERASE; CLOZAPINE; DEXTRO SERINE; DOPAMINE RECEPTOR STIMULATING AGENT; DYSBINDIN; GLUTAMIC ACID; METABOTROPIC RECEPTOR 8; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; TOLCAPONE; ZIPRASIDONE;

ALLELE; CHST8 GENE; COGNITION; COGNITIVE DEFECT; DOPAMINE RECEPTOR BLOCKING; DOPAMINE RELEASE; DRD2 GENE; DRUG MEGADOSE; EHF GENE; EXECUTIVE FUNCTION; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GPR137B GENE; HOMOZYGOTE; HUMAN; IL1A GENE; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SLC26A9 GENE; SYNAPTIC TRANSMISSION; TREATMENT RESPONSE; VERBAL MEMORY; WORKING MEMORY;

ANTIPSYCHOTIC AGENTS; COGNITION; DOPAMINE AGENTS; EXCITATORY AMINO ACID AGENTS; HUMANS; PHARMACOGENETICS; RECEPTORS, DOPAMINE; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 79958037920     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.3109/10673229.2011.581899     Document Type: Review

References (75)

1. Sanchez-Moreno J, Martinez-Aran A, Tabaŕes-SeisdedosR, Torrent C, Vieta E, Ayuso-Mateos JL. Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom 2009;78:285-97.
2. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30. (Pubitemid 26074706)
3. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-28. (Pubitemid 34586949)
4. Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.Psychopharmacology (Berl) 2003;169:404-11. (Pubitemid 37255530)
5. Harvey PD,Meltzer H, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 2004;66:101-13. (Pubitemid 38041108)
6. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005;162:1888-95. (Pubitemid 41428618)
7. Malhotra AK, Burdick KE, Razi K, Bates JA, Sanders M, Kane JM. Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity? Schizophr Res 2006;87:181-4. (Pubitemid 44428123)
8. Keefe RS, Bilder RM, Davis SM, et al.; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007;64:633-47. (Pubitemid 46878665)
9. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007;64:1115-22. (Pubitemid 47529336)
10. Keefe RS, Malhotra AK,Meltzer HY, et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008;33:1217-28. (Pubitemid 351521707)
11. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161:780-96. (Pubitemid 38625331)
12. Glahn DC, Almasy L, Blangero J, et al. Adjudicating neurocognitive endophenotypes for schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2007;144B:242-9. (Pubitemid 46606651)
13. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009;35:528-48.
14. Lencz T, Smith CW, McLaughlin D, et al. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry 2006;59:863-71.
15. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000;57:549-59. (Pubitemid 30191193)
16. Trandafir A, Meary A, Schurhoff F, et al. Memory tests in first-degree adult relatives of schizophrenic patients: a metaanalysis. Schizophr Res 2006;81:217-26. (Pubitemid 43107696)
17. Toulopoulou T, Picchioni M, Rijsdijk F, et al. Substantial genetic overlap between neurocognition and schizophrenia: genetic modeling in twin samples. Arch Gen Psychiatry 2007;64:1348-55. (Pubitemid 350223552)
18. Need AC, Attix DK, McEvoy JM, et al. A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB. Hum Mol Genet 2009;18:4650-61.
19. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 2011;36:616-26.
20. Weinberger DR, Berman KF, Illowsky BP. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry 1988;45:609-15.
21. Bertolino A, Caforio G, Blasi G, et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004;161:1798-805. (Pubitemid 39314673)
22. Weickert TW, Goldberg TE, Mishara A, et al. Catechol-Omethyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004;56:677-82. (Pubitemid 39446850)
23. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007;90:86-96. (Pubitemid 46177559)
24. Dickinson D, Elvevag B. Genes, cognition and brain through a COMT lens. Neuroscience 2009;164:72-87.
25. Fan JB, Zhang CS, Gu NF, et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol Psychiatry 2005;57:139-44.
26. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001;98:6917-22. (Pubitemid 32538317)
27. Bilder RM, Volavka J, Czobor P, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002;52:701-7.
28. Rosa A, Peralta V, CuestaMJ, et al. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry 2004;161:1110-2. (Pubitemid 38735999)
29. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002;159:652-4. (Pubitemid 34274949)
30. Tsai SJ, Yu YW, Chen TJ, et al. Association study of a functional catechol-O-methyltransferase-gene polymorphism and cognitive function in healthy females. Neurosci Lett 2003;338:123-6. (Pubitemid 36140153)
31. Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004;75:807-21. (Pubitemid 39390488)
32. Mattay VS, Goldberg TE, Fera F, et al. Catechol Omethyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003;100:6186-91. (Pubitemid 36576952)
33. Apud JA,Mattay V, Chen J, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007;32:1011-20. (Pubitemid 46631983)
34. Goldman-Rakic PS. The cortical dopamine system: role inmemory and cognition.Adv Pharmacol 1998;42:707-11.
35. Liu L, Wong TP, Pozza MF, et al. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 2004;304:1021-4. (Pubitemid 38638102)
36. Cotman CW,MonaghanDT, Ganong AH. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu Rev Neurosci 1988;11:61-80. (Pubitemid 18081033)
37. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14:301-7. (Pubitemid 26151927)
38. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psych 1998;44:1081-9. (Pubitemid 28547143)
39. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005;57:577-85. (Pubitemid 40409697)
40. Kantrowitz, JT, Malhotra, AK, Cornblatt, B, et al. High dose D-serine in the treatment of schizophrenia. Schizophr Res 2010;121:125-30.
41. Tsai G, Lane HY, Yang P, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004;55:452-6. (Pubitemid 38338531)
42. Norton N, Williams HJ, Owen MJ. An update on the genetics of schizophrenia. Curr Opin Psychiatry 2006;19:158-64. (Pubitemid 44406127)
43. Burdick KE, Lencz T, Funke B, et al. Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet 2006;15:1563-8. (Pubitemid 43904822)
44. Burdick KE, Goldberg TE, Funke B, et al. DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophr Res 2007;89:169-72. (Pubitemid 44881303)
45. Donohoe G,Morris DW, Clarke S, et al. Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: a preliminary study. Neuropsychologia 2007;45:454-8. (Pubitemid 44828767)
46. Stefanis NC, Trikalinos TA, Avramopoulos D, et al. Impact of schizophrenia candidate genes on schizotypy and cognitive endophenotypes at the population level. Biol Psychiatry 2007;62:784-92. (Pubitemid 47374644)
47. Zinkstok JR, de Wilde O, van Amelsvoort TA, Tanck MW, Baas F, Linszen DH. Association between the DTNBP1 gene and intelligence: a case-control study in young patients with schizophrenia and related disorders and unaffected siblings. Behav Brain Funct 2007;3:19.
48. Luciano M, Miyajima F, Lind PA, et al. Variation in the dysbindin gene and normal cognitive function in three independent population samples. Genes Brain Behav 2009;8:218-27.
49. Hashimoto R, Noguchi H, Hori H, et al. A genetic variation in the dysbindin gene (DTNBP1) is associated with memory performance in healthy controls. World J Biol Psychiatry 2010;11:431-8.
50. Wolf C, Jackson MC, Kissling C, Thome J, Linden DE. Dysbindin-1 genotype effects on emotional working memory. Mol Psychiatry 2011;16:145-55.
51. Karlsgodt KH, Robleto K, Trantham-Davidson H, et al. Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance. Biol Psychiatry 2011;69:28-34.
52. Weickert CS, Straub RE, McClintock BW, et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 2004;61:544-55. (Pubitemid 38747309)
53. Bray NJ, Preece A, Williams NM, et al. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression.Hum Mol Genet 2005;14:1947-54. (Pubitemid 41418031)
54. Numakawa T, Yagasaki Y, Ishimoto T, et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 2004;13:2699-2708. (Pubitemid 39485418)
55. Dickman DK, Davis GW. The schizophrenia susceptibility gene dysbindin controls synaptic homeostasis. Science 2009;326:1127-30.
56. Tang TT, Yang F, Chen BS, et al. Dysbindin regulates hippocampal LTP by controlling NMDA receptor surface expression. Proc Natl Acad Sci U S A 2009;106:21395-400.
57. Papaleo F, Weinberger DR. Dysbindin and schizophrenia: it's dopamine and glutamate all over again. Biol Psychiatry 2011;69:2-4.
58. Funke B, Finn CT, Plocik AM, et al. Association of the DTNBP1 locus with schizophrenia in a U.S. population. AmJ Hum Genet 2004;5:891-8. (Pubitemid 39390497)
59. Posthuma D, Luciano M, Geus EJ, et al. A genomewide scan for intelligence identifies quantitative trait Loci on 2q and 6p. Am J Hum Genet 2005;77: 318-26. (Pubitemid 41022713)
60. Hallmayer JF, Kalaydjieva L, Badcock J, et al. Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. Am J Hum Genet 2005;77: 468-76. (Pubitemid 41192652)
61. Williams NM, Preece A, Morris DW, et al. Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). Arch Gen Psychiatry 2004;61:336-44. (Pubitemid 38451542)
62. Zhang JP, Burdick KE, Lencz T, Malhotra AK. Meta-analysis of genetic variation in DTNBP1 and general cognitive ability. Biol Psychiatry 2010;68:1126-33.
63. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002;99:13675-80. (Pubitemid 35215440)
64. Detera-Wadleigh SD, McMahon FJ. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol Psychiatry 2006;60:106-14. (Pubitemid 44026593)
65. Opgen-Rhein C, Lencz T, Burdick KE, et al. Genetic variation in the DAOA gene complex: impact on susceptibility for schizophrenia and on cognitive performance. Schizophr Res 2008;103:169-77.
66. Goldberg TE, Straub RE, Callicott JH, et al. The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology 2006;31:2022-32.
67. O'Donovan MC, Craddock N, Norton N, et al.; Molecular Genetics of Schizophrenia Collaboration. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008;40:1053-5.
68. Riley B, Thiselton D, Maher BS, et al. Replication of association between schizophrenia and ZNF804A in the Irish Case-Control Study of Schizophrenia sample. Mol Psychiatry 2010;15:29-37.
69. Steinberg S,Mors O, Børglum AD, et al. Expanding the range of ZNF804A variants conferring risk of psychosis. Mol Psychiatry 2011;16:59-66.
70. Williams HJ, Norton N, Dwyer S, et al.; Molecular Genetics of Schizophrenia Collaboration (MGS), International Schizophrenia Consortium (ISC), SGENE-plus, GROUP
71. Malhotra AK, Riley B,Kendler KS, et al. Fine mapping of ZNF804A and genomewide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry 2011;16:429-41.
72. Esslinger C, Walter H, Kirsch P, et al. Neural mechanisms of a genome-wide supported psychosis variant. Science 2009;324:605.
73. Lencz T, Szeszko PR, Derosse P, et al. A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology 2010;35:2284-91.
74. Walter H, Schnell K, Erk S, et al. Effects of a genome-wide supported psychosis risk variant on neural activation during a theory-of-mind task. Mol Psychiatry 2011;16:462-70.
75. Walters JT, Corvin A, Owen MJ, et al. Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch Gen Psychiatry 2010;67:692-700.